BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/23/2022 1:56:15 PM | Browse: 746 | Download: 1599
 |
Received |
|
2022-03-27 12:03 |
|
Peer-Review Started |
|
2022-03-27 12:04 |
|
First Decision by Editorial Office Director |
|
2022-05-30 00:17 |
|
Return for Revision |
|
2022-05-31 17:32 |
|
Revised |
|
2022-06-30 11:39 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-09-26 03:46 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-10-04 22:47 |
|
Articles in Press |
|
2022-10-04 22:47 |
|
Edit the Manuscript by Language Editor |
|
2022-08-31 21:08 |
|
Typeset the Manuscript |
|
2022-11-11 15:55 |
|
Publish the Manuscript Online |
|
2022-11-23 13:56 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo and Sadishkumar Kamalanathan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dukhabandhu Naik, MD, Additional Professor, Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, 4th floor, Super-speciality block, JIPMER campus, Dhanvantri nagar, Puducherry, India -605006
, Puducherry 605006, Puducherry, India. drnaik2000@gmail.com |
| Key Words |
Dipeptidyl -peptidase 4; Diabetes mellitus; COVID-19; Mortality |
| Core Tip |
Patients with pre-existing comorbidities, particularly diabetes mellitus (DM), are at increased risk of complications from coronavirus disease 2019 (COVID-19). Beyond their glycemic effects, Dipeptidyl-peptidase 4 inhibitors (DPP-4i) have proven effective in COVID-19 individuals with DM. Available observational studies and trials have shown a significant mortality reduction in COVID-19 patients with DM when DPP-4i were continued during the course of illness. As a result, COVID-19 individuals with DM may choose DPP-4i as the preferred anti-diabetic medication if it is not contraindicated. |
| Publish Date |
2022-11-23 13:56 |
| Citation |
Narayanan N, Naik D, Sahoo J, Kamalanathan S. Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control. World J Virol 2022; 11(6): 399-410
|
| URL |
https://www.wjgnet.com/2220-3249/full/v11/i6/399.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v11.i6.399 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
